Market Intelligence, Clinical Progress, and High-Purity Reagents for Hippo Pathway Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LATS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LATS1 Kinase Domain / Full-Length Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Sf9/HEK293 expressed options. |
View LATS1 Products |
| Gene Delivery | LATS1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and Hippo pathway reporter assays. |
View LATS1 Products |
| Benchmark Ab | Anti-LATS1 Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP validation. |
View LATS1 Products |
| Validator | LATS1 siRNA Set Target-specific knockdown verification to confirm phenotype specificity. |
View LATS1 Products |
| Related Target A | YAP1 Primary downstream effector of LATS1; crucial for phosphorylation and nuclear translocation assays. |
View YAP1 Products |
| Related Target B | MST1 Upstream kinase in the Hippo pathway that phosphorylates and activates LATS1/2. |
View MST1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (LATS1 vs. LATS2) | High-purity LATS1 and LATS2 recombinant proteins available for comparative biochemical profiling. |
| Hippo Pathway Cascade Screening | Comprehensive pathway panel (MST1, LATS1, YAP1) for reconstructed in vitro phosphorylation assays. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| Off-Target Phenotypes | Validated siRNA sets included for orthogonal loss-of-function validation. |
Live LATS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The Hippo signaling pathway has emerged as a critical node in oncology, tissue regeneration, and tumor immunology. The race for LATS1 therapeutics is intensifying, with major players shifting focus from traditional oncology inhibition to leveraging LATS1/2 inhibition as a novel immuno-oncology strategy. By blocking LATS1/2, tumor cells release extracellular vesicles that stimulate a robust interferon response, priming CD8+ T cells and reversing resistance to immune checkpoint inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective small-molecule modulators and combination regimens with anti-PD-1 therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Vivace Therapeutics, Deciphera Pharmaceuticals | Solid Tumors, Triple-Negative Breast Cancer (TNBC) | Kinase Profiling & Selectivity (Need high-purity recombinant LATS1/2 kinase domains) |
| Gene Therapy / RNAi | Academic Spin-offs, Biotech Startups | Tissue Regeneration, Heart Failure | Stable Overexpression (Need high-titer Lentivirus for stable cell line construction) |
| Combination Therapies | Oncology Consortiums | Immuno-oncology (Cold Tumors) | Pathway Readout Validation (Need validated YAP1/LATS1 phosphorylation detection kits) |